Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more
Clinuvel Pharmaceuticals Ltd (CUV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.050x
Based on the latest financial reports, Clinuvel Pharmaceuticals Ltd (CUV) has a cash flow conversion efficiency ratio of 0.050x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$12.52 Million) by net assets (AU$249.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clinuvel Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Clinuvel Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Clinuvel Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clinuvel Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Satellogic V Inc
NASDAQ:SATL
|
0.147x |
|
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
|
0.020x |
|
Magnera Corp placeholder
NYSE:MAGN
|
0.002x |
|
Dodla Dairy Limited
NSE:DODLA
|
0.024x |
|
Xiangyang BOYA Precision Industrial Equipments Co. Ltd
SHE:300971
|
0.044x |
|
AUCTION TECH.GRP.LS-0001
F:684
|
N/A |
|
Hidrovias do Brasil S.A
SA:HBSA3
|
-0.062x |
|
Ocwen Financial Corp.
LSE:0KAS
|
-0.126x |
Annual Cash Flow Conversion Efficiency for Clinuvel Pharmaceuticals Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Clinuvel Pharmaceuticals Ltd from 2001 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$240.81 Million | AU$41.10 Million | 0.171x | -6.50% |
| 2024-06-30 | AU$203.01 Million | AU$37.05 Million | 0.183x | -18.59% |
| 2023-06-30 | AU$164.63 Million | AU$36.91 Million | 0.224x | -29.40% |
| 2022-06-30 | AU$125.56 Million | AU$39.87 Million | 0.318x | +62.78% |
| 2021-06-30 | AU$98.74 Million | AU$19.26 Million | 0.195x | -0.91% |
| 2020-06-30 | AU$72.07 Million | AU$14.19 Million | 0.197x | -39.00% |
| 2019-06-30 | AU$57.18 Million | AU$18.46 Million | 0.323x | +8.80% |
| 2018-06-30 | AU$39.42 Million | AU$11.69 Million | 0.297x | -23.88% |
| 2017-06-30 | AU$25.44 Million | AU$9.92 Million | 0.390x | +238.00% |
| 2016-06-30 | AU$17.83 Million | AU$-5.04 Million | -0.282x | +30.14% |
| 2015-06-30 | AU$11.21 Million | AU$-4.53 Million | -0.404x | -29.70% |
| 2014-06-30 | AU$15.43 Million | AU$-4.81 Million | -0.312x | +37.41% |
| 2013-06-30 | AU$13.84 Million | AU$-6.89 Million | -0.498x | +32.24% |
| 2012-06-30 | AU$13.64 Million | AU$-10.02 Million | -0.735x | -27.11% |
| 2011-06-30 | AU$16.41 Million | AU$-9.49 Million | -0.578x | -29.67% |
| 2010-06-30 | AU$26.43 Million | AU$-11.78 Million | -0.446x | -50.38% |
| 2009-06-30 | AU$37.05 Million | AU$-10.99 Million | -0.296x | -113.93% |
| 2008-06-30 | AU$51.81 Million | AU$-7.18 Million | -0.139x | -10.81% |
| 2007-06-30 | AU$65.39 Million | AU$-8.18 Million | -0.125x | +84.66% |
| 2006-06-30 | AU$13.99 Million | AU$-11.40 Million | -0.815x | +34.28% |
| 2005-06-30 | AU$7.45 Million | AU$-9.25 Million | -1.240x | -82.98% |
| 2004-06-30 | AU$8.85 Million | AU$-6.00 Million | -0.678x | -180.66% |
| 2002-06-30 | AU$10.31 Million | AU$-2.49 Million | -0.242x | -531.42% |
| 2001-06-30 | AU$13.45 Million | AU$-514.54K | -0.038x | -- |